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ABSTRACT 
Neuropilin 2 (NRP2) is a transmembrane receptor protein that was first 
discovered on neurons and then endothelial cells. On endothelial cells, it serves 
as co-receptor with the vascular endothelial growth factor receptor (VEGFR) to 
bind VEGF and induce a pro-(lymph)angiogenic intracellular signal. In addition to 
VEGF, NRP2 is also a receptor for semaphorin 3F (SEMA3F), which upon 
binding to NRP2 and Plexin A1 induces a strong anti-angiogenic signal. It is our 
hypothesis that SEMA3F could be a potentially effective treatment for metastatic 
cancers. A greater understanding of the regulation and expression of its receptor, 
NRP2, is needed. While NRP2 has been most robustly studied for its role in the 
vasculature, recent studies have shown that it is expressed on other cell types as 
well such as dendritic cells, T-cells, and visceral smooth muscle cells. In this 
study, we used western blot and immunohistochemistry to explore various 
different organs and cell types in an attempt to locate other novel locations of 
NRP2 expression. In particular, we found several new tissues that express NRP2 
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including the uterus and adipose tissue. Interestingly, NRP2 is expressed much 
more strongly in brown adipose tissue than white adipose tissue. In addition, we 
found that expression of NRP2 in adult organs is weaker than during 
development but is apparent, particularly on lung vascular EC and the intestinal 
lymphatic lacteal. In addition, we used several in vivo angiogenesis assays in 
order to help understand how NRP2 is regulated in the mature vasculature. We 
found that in the cutaneous wound healing assay, Nrp2 knockout mice healed at 
the same rate as their wild-type and heterozygous littermates. However, when 
delayed type hypersensitivity reactions were induced in these mice, the Nrp2 
knockouts demonstrated persistent swelling over a longer period of time in 
comparison to littermates. We also examined how the loss of NRP2 affected 
pathological angiogenesis by orthotopically injecting a murine syngeneic 
pancreatic adenocarcinoma cell line (Panc0H7) into the Nrp2 knockout mice. 
These mice displayed smaller tumors, less grossly apparent metastases, and 
less ascites. Taken together, these data suggest that NRP2 is important in 
physiological and pathological angiogenesis. Anti-NRP2 or SEMA3F strategies 
may represent promising anti-metastatic therapies.  
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INTRODUCTION 
 
The Process of Angiogenesis 
 Angiogenesis is the process by which new blood vessels are formed 
from existing blood vessels. This process is dependent upon endothelial cells 
(ECs) which line the lumen of all blood vessels and are the sole type of cell 
present in capillaries (W. Auerbach & R. Auerbach, 1994).  This process is 
separate from vasculogenesis which involves the formation of blood vessels in 
embryogenesis via precursor angioblasts (Noden, 1989). 
 The angiogenic cascade can be stimulated both physiologically and 
pathologically. In both cases, this occurs in response to hypoxic cellular 
conditions which leads to the secretion of growth factors that induce ECs to 
proliferate and sprout (Chung, Lee, & Ferrara, 2010). ECs then secrete matrix 
metalloproteinases (MMPs) which are proteolytic enzymes that degrade the 
basement membrane and allow for newly formed ECs to migrate towards the 
growth factors into the perivascular stroma (Efferet & Strohmeyer, 1995). ECs 
proliferate from the edge of the migrating vessel and then organize themselves to 
form new three-dimensional capillary structures (W. Auerbach & R. Auerbach, 
1994). The distinction between physiological and pathological angiogenesis 
involves the source of the growth factors. In physiological angiogenesis, the 
source is a hypoxic environment (stromal cells including fibroblasts, epithelial 
cells or immune cells) whereas in pathological angiogenesis, the source is a 
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tumor cell aberrantly releasing growth factors which may or may not be linked to 
hypoxia. 
Angiogenesis and Metastasis 
 Angiogenesis is required for tumors to grow beyond one millimeter in 
size, and it is also an essential aspect of cancer metastasis (Folkman, 1971). 
Cancer metastasis is the process by which tumor cells travel within blood vessels 
and lymphatic vessels into distant sites in the body (Sturk, 2004). The metastatic 
process is sequential and requires the following in order to occur: primary tumor 
growth, tumor angiogenesis, tumor cell detachment and invasion into capillaries, 
survival within the circulation, eventual embolism and arrest within the capillaries 
of distant organs, adhesion to the vessel wall and extravastation, and finally the 
establishment of a new microenvironment at the secondary site which requires 
both proliferation and angiogenesis (Fidler, 2003; Figure 1). 
 This process is similar for metastasis via lymphangiogenesis with some 
key differences. Many lymphatic capillaries that drain tumors have either missing 
basement membranes or ones that lack laminin and collagen XVIII (Skobe et al., 
2001) which may allow tumor cells to possess less invasive characteristics in 
order to invade the lymphatic system. In addition, extravasation may not be 
required in lymphatic metastasis (Sleeman, 2000). Ultimately, the tumor cells 
must reach the bloodstream. This can occur through several different 
mechanisms including drainage from the thoracic duct into the venous blood or 
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invasion into blood vessels within a lymph node itself (Haagensen et al., 1972 
and Tobler & Detmar, 2006).  
  
 
 
 
 
 
 
 
 
 
 
Figure 1 | Tumor Metastasis | The process of tumor metastasis involves a very precise 
step-wise process that begins when the primary tumor grows large enough to require a 
blood supply. Adapted from Fidler, 2003.  
 
 The process of cancer metastasis is incredibly detailed and requires 
both a highly invasive tumor cell and a new microenvironment that will sustain 
secondary tumor growth. This is the “seed”, invasive tumor cell, and “soil”, 
secondary site, hypothesis and both factors are absolute requirements in cancer 
metastasis (Fidler, 2002; Meric-Bernstam & Pollock, 2010).   
 Dr. Judah Folkman was the first to hypothesize that tumors required 
angiogenesis in 1971 when he discovered that tumors remain in a state of 
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dormancy unless they are able to establish a new blood supply (Folkman, 1971). 
His discovery sparked the investigation of anti-angiogenenic therapies for 
metastatic cancers which has been one of the most highly researched topics in 
cancer over the past 40 years. In addition, angiogenesis has been investigated in 
response to physiological conditions requiring new vessel growth that eventually 
resolves such as during endometrial thickening in the female menstrual cycle, 
cutaneous thickening following cell mediated Type IV hypersensitivity reactions 
(delayed type hypersensitivity) and those that do not resolve including wound 
healing or tissue regeneration (liver regeneration). Pathologic angiogenesis 
occurs during macular degeneration, psoriasis, arthritis, and cancer.  
Vascular Endothelial Growth Factor and its Receptors 
 One of the key components of angiogenesis is the idea of the 
angiogenic switch. Dr. Folkman described how the body tightly regulates 
angiogenesis by balancing proangiogenic and antiangiogenic molecules 
(Hanahan & Folkman, 1996). Under normal physiological conditions or 
homeostasis, inhibitors of angiogenesis outweigh or equal the promoters and 
new blood vessels are not formed. However, when a pathological phenotype or 
hypoxic cell begins to secrete proangiogenic growth factors, the balance can be 
shifted towards angiogenesis (Figure 2). 
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Figure 2 | Angiogenic Switch | Dr. Folkman’s angiogenic switch illustrates the delicate 
balance between endogenous inhibitors and activators of angiogenesis. The switch is 
turned on under hypoxic conditions when the levels of angiogenic activators are in 
excess of the inhibitors. From Hanahan & Folkman, 1996. 
 
 The scale can be tipped towards angiogenesis by a host of endogenous 
proangiogenic growth factors including acidic fibroblast growth factor (a-FGF, 
FGF-1), basic fibroblast growth factor (b-FGF, FGF-2), vascular endothelial 
growth factor (VEGF), transforming growth factor beta (TGF-β), transforming 
growth factor alpha (TGF-α), platelet derived growth factor (PDGF), placental 
growth factor (PIGF), interleukin-8 (IL-8), and angiopoietin-1 and 2 (Ang-1 and 
Ang-2) (Hannahan & Folkman, 1996; Longo, 2012). VEGF, first discovered as 
vascular permeability factor, is perhaps the most crucial and most studied of the 
growth factors which regulate tumor angiogenesis (Dvorak et al., 1995). While it 
was first discovered in regards to vascular permeability, its role has also been 
confirmed in stimulation of EC proliferation, tube formation, and induction of 
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endothelial cells to synthesize proteolytic enzymes (Longo, 2012). Since its 
discovery in 1983, five VEGF-related genes have been identified including 
VEGF-A, VEGF-B, VEGF-C, VEGF-D and VEGF-E, all of which are 
approximately 40 kDa as dimers (Ferrara, 1996). Posttranslational modification of 
the VEGF gene makes several different isoforms, but VEGF121 and VEGF165 
(denoted by the number of amino acids in the protein; 121 in human and 120 in 
mouse; 165 in human and 164 in mouse) are the two most common forms found 
overexpressed in human tumors (Takahashi, 2011). VEGF165 has a heparin-
binding domain (exon 7) that aids in binding to the extracellular matrix and keeps 
the protein local to its site of secretion, while VEGF121 lacks this domain and is 
freely soluble and acts at a distance (Klagsbrun, D’Amore, 1996). 
 The VEGFs bind to two distinct families of receptor proteins: three 
tyrosine kinase VEGF receptors and two other co-receptors known as neuropilin-
1 and neuropilin-2 (NRP1, NRP2). All three VEGFRs have six-seven extracellular 
immunoglobulin domains and tyrosine kinase machinery in the cytosolic region 
(Ferrara, Gerber, & LeCouter, 2003). Upon binding to VEGF, the receptor 
undergoes typical tyrosine kinase behavior: dimerization and 
autophosphorylation which initiates an intracellular signaling cascade. VEGFR1 
binds VEGF-A, VEGF-B, and PIGF and is found on macrophages, monocytes, 
and ECs (Roskoski, 2008). In general, VEGF-A binds VEGFR1 with the highest 
affinity but the receptor’s tyrosine kinase activity is relatively low in comparison to 
its other family members (Seetharam et al., 1995). VEGFR2 binds VEGF-A, 
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VEGF-C (mature form), VEGF-D (mature form), and VEGF-E and is found on 
ECs, hematopoietic cells, neuronal cells, and some tumor cells (Roskoski, 2007). 
Although, it has a slightly lower affinity for VEGF-A than VEGFR1, it induces a 
much greater tyrosine kinase activity and is thought to be the major regulator of 
VEGF-induced cell survival, mitogenesis, and angiogenesis (Ferrara, Gerber, & 
LeCouter, 2003). It primarily signals through the PLCγ-PKC-Raf-MEK-MAPK 
pathway which promotes DNA synthesis in ECs (Shibuya & Claesson-Welsh, 
2003). In addition, it can activate the Shb-PI3K pathway which leads to actin 
stress fiber organization and cell migration (Roskoski, 2007). Due to its major 
role in angiogenesis, VEGFR2 has been highly investigated for potential 
antiangiogenic therapies. VEGFR3 is the smallest of the VEGF receptors at 110 
kDa, binds VEGF-C and VEGF-D (both pro- and processed forms), and is only 
found on vascular ECs during development (Kukk et al., 1996). After 
development, it is expressed solely in the lymphatic vasculature by lymphatic 
ECs (Kaipainen et al., 1995). Transgenic VEGFR3 knockout mice are lethal at 
mid-gestation which implies that the receptor is essential for normal vasculature 
development (Dumont et al., 1998). 
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Figure 3 | The VEGF Receptors | VEGFR1, VEGF2, and VEGFR3 are the three 
tyrosine kinase receptors for the VEGF family of growth factors. Each ligand has 
differing affinity for each receptor. NRPs are also receptors for VEGF but are not shown. 
Adapted from Ruiz de Almodovar et al, 2009. 
 
The Neuropilin Receptors 
 VEGF is also a ligand for a second family of protein receptors, the 
neuropilins (human: NRP; mouse: Nrp). Two NRPs have been identified – NRP1 
and NRP2. They are each 130 kDa transmembrane glycoproteins which share 
45% amino acid homology. Despite such similar primary structure, the NRP1 and 
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NRP2 genes map to entirely different chromosomes. In humans, they map to 
10p12 and 2q34, respectively (Klagsbrun, Takashima & Mamluk, 2002). Each 
NRP protein has five extracellular domains which have been coined a1, a2, b1, 
b2, and c (Klagsbrun & Eichmann, 2005). In addition, each protein has an 
intracellular domain of 40 amino acids that has been shown to interact with a 
protein known as neuropilin interacting protein (NIP) or RGS–GAIP-interacting 
protein (GIPC) but no known signaling motif has yet been elucidated (Cai & 
Reed, 1999). Interestingly, both NRP proteins share the identical final three 
amino acids at their C-terminal end, SEA (Bielenberg et al., 2006). Recently, 
deletion of the SEA domain of NRP1 has been shown to inhibit PIGF signaling in 
medulloblastoma indicating that it may have a key role yet to be discovered 
(Snuderl et al., 2013).  
 The first identification of NRP came in 1987 when Fujisawa described 
an antigen that was specific for the monoclonal antibody A5 (Takagi et al., 1987).  
This mAb targeted the neuropile in the optic tectum of Xenopus laevis which 
ultimately led to NRP’s neurological nomenclature. It was not until 1995 that this 
antigen was given the name neuropilin when it was revealed by 
immunohistochemistry to be present on Xenopus principal olfactory axons 
(Satoda et al., 1995). In that same year, NRP was shown to be essential in 
development when Fujisawa described that chimeric mice overexpressing Nrp 
were embryonic lethal. The abnormalities found in the embryos included both 
nervous system and vascular defects. In particular, they found increased 
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numbers and dilation of blood vessels, malformed hearts, and defasciculation of 
nerve fibers (Kitsukawa et al., 1995). In 1997, a second NRP protein (NRP2) was 
identified in the developing mouse spinal cord which was expressed differentially 
from NRP1 (Chen et al., 1997).   
 The first known ligand for NRP, the semaphorin class III (SEMA3) 
family of axonal guidance molecules, was also identified in 1997 (Kolodkin et al., 
1997). The semaphorins are divided into eight classes and the SEMA3s are a 
group of seven proteins which are all approximately 100 kDa and the only class 
that binds to NRPs (Bielenberg & Klagsbrun, 2007). The SEMA3 family has 
seven members, SEMA3A, B, C, D, E, F and G. In particular, SEMA3F 
specifically binds NRP2 while SEMA3A specifically binds NRP1, and SEMA3B 
binds both NRPs. The first SEMA3 reported to interact with NRP was SEMA3A 
which was shown to repel axons and cause a functional collapse of growth cones 
in the dorsal root ganglia (Fujisawa, 2002). In particular, the SEMA3s bind to the 
a1a2 and b1b2 domains of NRP (Mamluk et al., 2002) SEMA3s dimerize via a 
cysteine residue and this dimerization is essential for NRP binding (Adams et al., 
1997). In the neuronal guidance pathway, NRP/SEMA3 requires another family 
of receptors, the plexins, in order to provide signaling capabilities (Puschel, 
2002). In particular, SEMA3F signals via NRP2/Plexin A1 in tumor cells and EC 
(Shimizu et al., 2008). SEMA3E is an exception within the class 3 SEMAs as it 
does not bind directly to either NRP but binds directly to Plexin D1 (Klagsbrun 
and Shimizu, 2010). 
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 VEGF was found to be a ligand for NRP on ECs in 1998 (Soker et al., 
1998) and was later shown to bind to the b1b2 domain in NRP1 (Mamluk et al., 
2002). Both NRPs bind VEGF165 but vary in their specificity for the other VEGF 
family members. In particular, NRP1 binds VEGF-A,B, E, and PIGF2 while NRP2 
binds VEGF-A,C,D and PIGF2 (Klagsbrun, Takashima, & Mamluk 2002; Gaur et 
al., 2009). Mechanistically, VEGF-A binds to both NRP1 and VEGFR2 forming a 
bridge between each receptor and enhancing the angiogenic signal (Soker et al., 
2002). NRP2 is a co-receptor for VEGF-A with VEGFR2 and for VEGF-C/D with 
VEGFR3 (Favier et al., 2006). Because both the SEMA3s and VEGFs require 
binding to the b1b2 domain, they are competitive inhibitors of one another; and 
VEGF and SEMA3 have similar binding affinities for NRP (Mamluk et al., 2002).  
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Figure 4 | Neuropilin and its Ligands | A) The SEMA3s and their specificity for both 
NRP1 and NRP2. NRP requires the plexin family of receptors in order to bind the 
SEMA3s. B) The VEGF family of growth factors and its specificity for the NRP receptors. 
These require the VEGF family of receptors as co-receptors and are expressed 
differentially on cells. From Gaur et al., 2009.  
  
 Similar to the Nrp1 overexpressing chimeric mice, Nrp1 knockout mice 
are embryonic lethal at E12.5-E13.5 (Kawasaki et al., 1999). These embryos 
 13 
displayed a greatly disorganized vasculature in the yolk sac suggesting that 
NRP1 is essential in embryonic vessel formation. Embryos that are null for both 
Nrp1 and Nrp2 show an even more drastic phenotype than the Nrp1 knockouts. 
These embryos survived only until E8.5 and presented with numerous 
hemorrhages and a vascular phenotype similar to VEGF or VEGFR2 knockout 
mice (Takashima et al., 2002).  
Nrp2 Transgenic Mice 
 Nrp2 knockout mice show a loss in small lymphatic vessel and capillary 
formation during development but are viable (Yuan et al., 2002; Figure 5). This 
severe reduction in small lymphatic vessel number was found in many different 
tissues and correlated with a decrease in DNA synthesis in LECs. Other vessel 
types including arteries, veins and large lymphatic vessels all developed normally 
(Yuan et al., 2002). More recently, it was shown that double heterozygote 
Nrp2/VEGFR3 mice demonstrated an inability to sprout lymphatic vessels in 
response to VEGF-C only cementing the observation that proper Nrp2 function is 
important in lymphangiogenesis (Xu et al., 2010). 
 The abnormal lymphatic vessel structure in Nrp2 knockout mice has led 
many to believe that NRP2 may play a key role in lymphangiogenesis and cancer 
metastasis. An antibody that targeted the b1b2 binding domain of Nrp2 was 
shown to decrease VEGF-C mediated tumor lymphangiogenesis using a murine 
corneal micropocket assay (Caunt et al., 2008). In addition, it was found that the 
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anti-Nrp2 antibody caused a reduction in metastasis and concurrent disruption of 
tumor lymphatic vessel formation. 
 Despite its largely normal cardiovascular phenotype, the Nrp2 deficient 
mice show significant loss of neuronal function. In particular, they demonstrate 
defects in cranial nerve development, spinal sensory axons, and in hippocampal 
mossy fiber axons (Chen et al., 2000). This phenotype is likely observed as a 
result of loss of SEMA3F mediated repulsion which normally guides nerves into 
their proper orientation via Nrp2.  
 Most recently, Nrp2 knockout mice were shown to have an increase in 
smooth muscle (SM) dependent bladder contractility. The mice demonstrated 
increased bladder filling pressures and enhanced tension generation when 
bladder tissue when investigated ex vivo (Bielenberg et al., 2012). From this 
data, it is likely that Nrp2 plays a key role in relaxing the bladder and is now 
being investigated as a potential target to regulate visceral SM contractility. 
 In our laboratory, we have both Nrp2+/LacZ and Nrp2+/gfp transgenic mice. 
In both cases, the mice have an insert after exon 1 where either LacZ or GFP is 
knocked-in while Nrp2 is knocked out. The mice maintain the endogenous Nrp2 
promoter and therefore the expressed LacZ or GFP represents endogenous 
Nrp2 in vivo. Interestingly, despite their similarities in genetic creation, the 
Nrp2LacZ/LacZ mice die at birth whereas the Nrp2gfp/gfp mice are viable. 
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Figure 5 | Lymphatic vessels in Nrp2 knockout mice | Dorsal skin of E17 embryos 
from Nrp2 transgenic mice stained with VEGFR3, a lymphatic endothelial cell marker 
show severely reduced numbers of lymphatic capillaries in the dermis of knockout (-/-) 
mice compared to heterozygous mice. From Yuan et al., 2002.  
 
Neuropilin Expression 
 Despite being first encountered in neuropiles, a constantly growing 
knowledge of NRP has shown the receptor to be found in a variety of different 
organs and cell types (Gagnon et al., 2000). In the nervous system, NRP1 is 
expressed on both sensory and sympathetic neurons. NRP2, however, is only 
found on sympathetic neurons and, thus, only sympathetic neurons such as the 
superior cervical ganglia (SCG) are repelled by SEMA3F (Bagri and Tessier-
Lavigne, 2002).  
 In the embryonic endothelium, there is also a stark contrast in NRP 
expression. In the early vascular structures of the chick known as blood islands, 
both NRP1 and NRP2 are expressed. Further along in development, however, 
NRP1 and NRP2 are found preferentially on arterial and venous EC, respectively 
 16 
(Herzog, Kalcheim, Kahane, Neufield, 2001). In addition, lymphatic EC have 
been shown to preferentially express NRP2 which gives further precedent to the 
lymphatic phenotype found in the Nrp2 knockout mice (Yuan et al., 2002). After 
birth, NRPs are dramatically down-regulated on neurons and EC. In the mature 
(adult) endothelium, the pattern of NRP2 expression is more heterogeneous but 
can be found on blood capillaries, veins, and lymphatics (Bielenberg et al., 2006).  
 As the wealth of NRP knowledge grows, new cell types are being 
discovered that express NRP with unknown functions.  In particular, NRP1 has 
been shown to be widely expressed in various types of epithelial cells (Gagnon et 
al., 2000; Kurschat et al., 2006). NRP2 has recently been shown to be expressed 
in visceral (but not vascular) smooth muscle cells (SMCs) and most strongly in 
the bladder (Bielenberg et al., 2012). Due to the increasing number of cell types 
which express NRP, there is a great incentive to understand more fully the 
underlying mechanism of NRP expression beyond solely neuronal and vascular 
activity.  
Neuropilins in Cancer 
 The NRPs are expressed in a wide range of tumor types. In general, 
carcinomas more commonly express NRP1 while other non-carcinoma tumor 
types commonly express NRP2 but there is some overlap (Bielenberg et al., 
2006, Figure 6). The first two cancer cell lines reported to express NRP1 were 
the prostate cancer cell line PC3 and the breast cancer cell line MDA-MB-231 
(Soker et al., 1998). Since then, NRP1 has been found in tumor biopsies from 
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bladder, kidney, colon, pancreas, skin, ovarian, and lung carcinomas as well 
(Wey, Stoeltzing, & Ellis, 2004; Neufeld et al., 2005)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 | NRP1/2 Expression in Human Cancer Cell Lines | RT-PCR of various 
carcinoma and non-carcinoma human cell lines shows that NRP1 is more commonly 
expressed in carcinomas while NRP2 is more strongly expressed in cells of other 
origins. However, there is some overlap in expression. Cell lines from left-right: PC3, 
MDAMB231, 253JB5, SN12PM6, A375SM, U87MG, Sy5Y, HUVEC. From Bielenberg et 
al., 2006.  
 
 Malignant prostate carcinoma tissue samples were shown to have a 
ten-fold increase in NRP1 expression compared to normal tissue 
(Vanveldhuizen, 2003). In addition, when NRP1 was overexpressed in AT2.1 rat 
prostate cancer cells, the resulting tumors increased in size up to 7-fold over 
control tumors and were less apoptotic (Miao et al., 2000). Histology indicated 
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that the tumors had increased vessel density, increased levels of VEGF protein, 
and hyperproliferative vessels within the tumor (Miao et al., 2000). How tumor 
cells that express only NRP1 and no tyrosine kinase VEGFRs (and therefore 
cannot have VEGF autocrine signaling) could increase in size compared to tumor 
cells not expressing NRP1 was perplexing. One hypothesis derived from this 
finding is that NRP1 could be acting as a reservoir and holding VEGF on the 
tumor surface or within the tumor microenvironment thus increasing the gradient 
of VEGF toward the tumor which would chemo-attract new vessel sprouts. This 
hypothesis could be expanded to include NRP2 which may sequester VEGF-A, 
C, and D and therefore induce both angiogenesis and lymphangiogenesis. 
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Figure 7 | VEGF Sequestration Hypothesis | The hypothesis that cells which express 
NRP act as a reservoir for VEGF by binding VEGF and holding it near the cell surface at 
a high concentration/gradient. This high concentration of VEGF then causes an 
accelerated and stronger angiogenic response. 
  
 Several breast cancer cell lines have been shown to express NRP. Rat 
carcinogen-induced carcinomas express both NRP1 and NRP2 (Heffelfinger et 
al., 2004). There are also numerous examples of invasive or metastatic 
mammary carcinomas cell lines that express NRP1 while non-metastatic cell 
lines do not (Soker et al., 1998). In addition, a peptide inhibitor of NRP1 resulted 
in an increase in apoptosis in breast cancer cells (Barr et al., 2005).  
 20 
 NRP2 is most commonly expressed in non-carcinomas and has been 
found in melanoma cells, glioblastoma cells, and neuroblastoma cells. Its strong 
expression in these cell lines indicate that it likely has a neural crest origin 
(Bielenberg et al., 2006). However, its involvement in carcinomas has been 
shown as well. In particular, several studies have shown increased levels of 
NRP2 in the most common type of pancreatic cancer, pancreatic ductal 
adenocarcinoma (PDAC).  
  In three different pancreatic cancer cell lines (ASPC-1, CAPAN-1, 
PANC-1), there were higher mRNA levels of both NRP1 and NRP2 than any of 
the three VEGF receptors. This was a significant increase from normal 
pancreatic tissue which is devoid of NRP1 expression and lowly expresses NRP2 
only in islet and acinar cells (Fukahi et al., 2004). Another study used shRNA to 
knockdown NRP2 expression in PDAC cells leading to decreased Akt activation 
and reduced survival signaling when phospho-Akt was measured. In addition, 
shRNA-NRP2 caused up to a 70% decrease in migration, and a 50% -70% 
decrease in invasion ability. There was no affect on PDAC proliferation in vitro. 
When these cells were grown in vivo, tumors were 63% - 95% smaller than 
controls and had reduced blood vessel lumen size (Dallas et al., 2008).  Taken 
together, these data suggest that systemic inhibition of NRP2 inhibits 
tumorigenicity and progression (direct effects on NRP2-expressing tumor cells) 
as well as tumor size and angiogenesis (direct effects on NRP2-expressing 
vessels).  
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 PDAC is the fourth most deadly cancer in the United States with a 
median survival of only 6 months (Jemal et al., 2008). PDAC has a five-year 
survival of less than 5% which is the lowest of any solid tumor (Jemal et al., 
2008; Jemal et al., 2009). Because only 20% of pancreatic tissue is necessary 
for normal physiological function, it is rarely the primary tumor that causes 
mortality (Douglass and Penetrante, 1990). Instead, the most common cause of 
death is due to liver failure caused by metastasis (Douglass and Penentrante, 
1990). The discouraging survival data for PDAC show that a potential therapeutic 
target is urgently needed.  
Class 3 Semaphorins in Angiogenesis 
 Although the SEMA3s were first discovered as axonal guidance 
molecules, it has been shown that they have a key role in angiogenesis and 
vasculogenesis as well. Of the SEMA3s, while SEMA3A and SEMA3F are 
considered antiangiogenic, SEMA3C has proangiogenic properties. SEMA3A 
and SEMA3F are capable of inhibiting EC proliferation, survival, and cord 
formation with differing opinions on the mechanism (Shimizu et al., 2008; 
Acevado et al., 2008; Banu et al., 2006). Some have suggested that SEMA3A 
and SEMA3F inactivate integrins on ECs and cause disruption of angiogenesis 
and vascular remodeling (Serini et al., 2003). Others argue that they act by 
inhibiting either VEGF or b-FGF induced angiogenesis and cause a pro-apoptotic 
and cell repellant phenotype (Guttmann-Raviv et al., 2007). While others suggest 
that SEMA3F de-polymerizes F-actin stress fibers (called “collapse”) in both 
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tumor cells and EC and thereby inhibits migration, angiogenesis, and metastasis 
(Shimizu et al., 2008). In addition, numerous studies have shown that cancer 
cells transfected with SEMA3F cause ensuing tumors to become less 
vascularized, have decreased metastatic potential, and show an encapsulated 
phenotype (Bielenberg et al., 2004; Kessler et al., 2004; Kigel et al., 2008; Wu et 
al., 2011).  
 Due to their antitumor and antimetastatic properties, the SEMA3s have 
been shown to be tumor suppressor genes in some instances. For example, loss 
of heterozygosity of the 3p21.3 region has been positively correlated with lung 
cancer (Roche et al., 1996; Sekido et al., 1996). This region was later shown to 
be connected to a deletion of SEMA3B and SEMA3F (Futamura et al., 2007). In 
addition, deletion of SEMA3F has been correlated with advanced stage lung 
cancer and melanoma (Bielenberg et al., 2004; Lantuejoul et al., 2003).  
In vivo Angiogenesis Assays 
 A number of assays have been developed that highlight angiogenesis in 
its vast number of physiological roles. In this study, we utilized two of these 
assays while investigating our Nrp2 transgenic mice: cutaneous wound healing 
and induced delayed-type hypersensitivity. 
A) Cutaneous Wound Healing 
 Acute wound healing occurs in a sequential manner that involves four 
overlapping yet definitive phases: hemostasis, inflammation, proliferation, and 
remodeling (see Figure 8). Hemostasis begins immediately following infliction of 
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the wound with constriction of blood vessels and fibrin clot formation in order to 
control the bleeding (Gosain and DiPietro, 2004). The early inflammatory phase 
(about 24 hours after wounding), is characterized by a large number of 
polymorphonuclear leukocytes (PMNs) or neutrophils that arrive at the wound 
site and engulf bacteria to prevent infection (Broughton et al., 2006). The 
accumulation of macrophages around the wound site identifies the late 
inflammatory phase (about 48 hours after wounding). Similar to neutrophils, 
macrophages endocytose bacteria and damaged tissue. Near the end of the 
inflammatory phase, however, they begin to recruit cells for the proliferative 
phase and are stimulated by the low oxygen content to recruit EC’s and other 
cells necessary for angiogenesis (Mosser and Edwards, 2008).  
 The proliferative phase begins about 72 hours after wounding and key 
components of this phase include collagen and granulation tissue formation, 
fibroblast migration, and re-epithelialization at the wound site (Gosain and 
DiPietro, 2004). Concurrently, angiogenesis is essential in this phase of wound 
healing and is directly stimulated by hypoxia and lactic acid in the wound site. 
The final phase of healing is the remodeling phase which includes capillary 
regression to normal levels and is characterized by equal levels of collagen 
synthesis and breakdown (Greenhalgh, 1998).  
 In the cutaneous wound healing assay employed in this study, a punch 
of skin is removed from the back of the mouse and wound healing is monitored 
over a ten day period. Because angiogenesis is most crucial from day three 
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onward during the proliferative phase, we paid careful attention to that range in 
the healing process. It is of importance to note that the angiogenesis induced in 
this assay is largely hypoxia dependent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 | Wound Healing Steps | Wound healing begins with injury (a) where the 
clotting cascade is immediately induced identified by the fibrin clot (b). In the early 
inflammatory phase (c), neutrophils (PMNs) are the primary cell type present. In the late 
inflammatory phase (d), the PMNs are replaced by macrophages. In the proliferative 
phase (e), fibroblasts, keratinocytes, and ECs are recruited to the wound site to re-
epithelialize the tissue and angiogenesis is paramount here. Remodeling (f) is a long 
term process after wounding. From Beanes et al., 2003.  
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B) Induced Delayed-Type Hypersensitivity Reaction 
 Delayed type hypersensitivity reactions of type IV hypersensitivity 
reactions are thus named because their response to an allergen is non-
immediate and can take up to several days to reach its full impact. This is in stark 
contrast to immediate hypersensitivity reactions which usually occur within 12 
minutes of exposure. Type IV hypersensitivity reactions are unique in that they 
are entirely cell mediated and do not involve an antibody response (Uzzaman & 
Cho, 2012). 
 When exposed to the allergen, CD4+ helper T cells known as Th-1 cells 
become activated and secrete IFN-γ which is a potent stimulator of 
macrophages. The macrophages secrete large amounts of TNF-α and IL-1, both 
of which cause even more macrophages to be recruited and result in a significant 
inflammatory response (Czarnobilska et al., 2007). 
 In order for macrophages and other factors to accumulate at the site of 
allergen affliction, some modification to the vasculature and/or lymphatic 
vasculature is required. For example, mice over expressing VEGF164 display 
prolonged swelling when exposed to the same DTH assay employed in this study 
(Detmar et al.,1998). The angiogenesis and lymphangiogenesis anticipated in 
this assay is mediated by growth factors and, unlike the wound healing assay, 
not by hypoxia. Therefore, these two assays allow us to explore angiogenesis 
from two different origins. 
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 In conclusion, the wound healing assay allows us to explore hypoxia 
induced angiogenesis whereas the DTH assay allows us to explore growth 
factor/cytokine induced angiogenesis. Tumor angiogenesis and metastasis can 
be induced by both mechanisms so it is imperative to study angiogenesis from 
both perspectives.  
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SPECIFIC AIMS 
  
 It is our laboratory’s hypothesis that NRP2 is pivotal in the growth and 
metastasis of cancer. In particular, we believe that using SEMA3F to target 
NRP2 could be potentially efficacious in a number of different metastatic tumor 
types. Because NRP2 is the target of this treatment, it is essential to more fully 
understand where NRP2 is expressed physiologically. A more robust 
understanding of the organs and cell types which express NRP2 could give an 
idea of how specific SEMA3F therapy may be on tumor angiogenesis or 
lymphangiogenesis. Previous studies in our laboratory have shown that adult 
expression of NRP2 on ECs is not well understood and very heterogeneous. If 
NRP2 could eventually be used as a therapeutic target, its regulation and 
expression pattern should be uncovered. We will also use Nrp2/GFP and 
Nrp2/LacZ transgenic mice to more fully understand how the loss of NRP2 
affects angiogenesis in both the physiological and pathological settings. Our 
hypothesis is that NRP2 is important for normal angiogenesis. Therefore, 
physiological processes involving angiogenesis such as wound healing and 
tissue expansion resulting from delayed-type hypersensitivity reactions would be 
impacted by the loss of NRP2. In addition, we predict that tumor angiogenesis 
and growth would also be impeded in the knockout mice.  
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In summary, the three main aims of this study were: 
1. To identify the organs and cell types which most strongly express 
NRP2 in vivo. 
2. To analyze the role of NRP2 is physiological angiogenesis including 
wound healing and delayed type hypersensitivity reaction. 
3. To analyze the role of NRP2 in pathological angiogenesis; in 
particular tumor metastasis via angiogenesis and 
lymphangiogenesis.  
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METHODS 
Protein Isolation 
 Tissue samples were flash frozen in liquid nitrogen and stored at -80°C. 
Tissue samples were pulverized using a 59014N Biopulverizer (BioSpec 
Products) and samples were re-suspended in Radio Immuno Precipitation Assay 
(RIPA) Buffer (50 mM Tris-Hcl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% sodium deoxysulfate; Boston BioProducts) containing EDTA-
free protease inhibitor cocktail (Roche Applied Science). Samples were then 
agitated using Vibra Cell sonicator (Sonics Materials) until tissue samples 
became homogenized in solution. Samples were placed on ice for 15 minutes 
and then centrifuged for 10 minutes at 14,0000 RPM and 4°C. The supernatant 
was then collected and stored at  -20°C.  
Protein Assay 
 Total protein concentration of tissue sample lysates was quantified 
using Bio-Rad DC Protein Assay Kit utilizing the Lowry protein assay method. 
Protein concentrations were determined using a standardized serial dilution of 
Albumin from Bovine Serum (BSA, Fisher) in a 96-well flat bottom plate 
(Corning). Each well contained 5 µL of protein sample, 25 µL of 2% Protein 
Assay Solution S in Solution A, and 200 µL of Solution B (Bio-Rad). Samples 
were incubated in colorimetric solution for 15 minutes and then read in VersaMax 
Microplate Reader (Molecular Devices) at 750 nm using Softmax Pro 48 
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Program. Data was then collected in Microsoft Excel and sample concentrations 
were determined using best-fit line obtained from standard BSA samples.  
SDS-PAGE Gel Preparation 
 The separating layer of gel was prepared by combining 3.75 mL of 30% 
acrylamide/0.8% bisacrylamide (National Diagnostics), 3.75 mL of 4x Tris-
HCl/SDS pH 8 (National Diagnostics), 7.5 mL H2O, 50 µL of 10% ammonium 
persulfate, and 10 µL Tetramethylethylenediamine (TEMED; JT Baker Inc.). 
Separating solution was added between two glass plates separated by a 1.5mm-
thick spacer in a gel-casting apparatus and allowed to harden for 30-60 minutes. 
The stacking layer of gel was prepared by combining 0.65 mL of 30% 
acrylamide/0.8% bisacrylamide (National Diagnostics), 1.25 mL of 4x Tris-
HCl/SDS pH 8 (National Diagnostics), 3.05 mL H2O, 25 µL of 10% ammonium 
persulfate, and 5 µL TEMED. Stacking solution was then added above hardened 
separating layer in gel cast. A 10-well comb was added to the stacking layer and 
allowed to harden for 30-60 minutes. Prepared gels were either used 
immediately or stored at 4°C in a moist environment.  
Western Blot 
 Protein samples were prepared in equal concentrations to ensure equal 
loading. 6X SDS Reducing Sample Buffer (Boston BioProducts) was added to 
each sample at a final concentration of 1X. Samples were boiled for 5-10 minutes 
and then loaded into 7.5% SDS-PAGE gel immersed in Running Buffer (25 mM 
Tris, 192 mM glycine, 0.1% SDS, pH 8.3; Boston BioProducts). Proteins were 
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separated via electrophoresis for 2 hours at 100 V and then transferred to 
nitrocellulose membrane (Bio-Rad). Membranes were immersed in Transfer 
Buffer (25 mM Tris, 192 mM glycine, pH 8.4; Boston BioProducts) with 20% 
methanol and allowed to transfer overnight at 4°C and 75 mA or two hours at 
room temperature and 300 mA.  
 Membranes were then blocked with 5% blotting-grade blocker non-fat 
dry milk (Bio-Rad) in Tris Buffered Saline (10 mM Tris-HCl, 150 mM NaCl, pH 
7.4) with 1% Tween-20 (TBS-T) for 1 hour at room temperature with mild 
agitation. Blocked membranes were then incubated with rabbit anti-mouse Nrp2 
primary antibody (Cell Signaling) or mouse anti-GAPDH primary antibody 
(Millipore) for two hours at room temperature or overnight at 4°C. Membranes 
were subsequently washed three times in TBS-T, 15 minutes each, and then 
incubated with horseradish peroxidase (HRP) linked anti-rabbit or anti-mouse 
IgG secondary antibody (GE Healthcare) for one hour at room temperature. After 
three subsequent washes in TBS-T, Western Lightning Plus-ECL Oxidizing and 
Enhanced Luminol Reagent (Perkin Elmer) were mixed in equal proportions and 
added to membranes for 3 minutes, exposed to Hyblot Film (Denville) for up to 
20 minutes, depending on band intensity. 
 For immunoprobing with a different primary antibody, membranes were 
incubated in Restore Western Blot Stripping Buffer (Thermo Scientific) for 15 
minutes for removal of previous antibody. Membranes were then blocked, 
incubated, and exposed according to procedure above. 
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Immunohistochemistry 
 Paraffin embedded sections were warmed at 58°C on slide warmer for 
15-20 minutes or until dry. Sections were then deparaffinized in xylene for 4 
minutes and rehydrated in decreasing concentrations of ethanol for 2 minutes 
each (100% twice, 95% twice, 70%, 50%). Slides were placed in PBS for 5 
minutes and then subjected to either sodium citrate or proteinase K antigen 
retrievel. For sodium citrate, sections were placed in coplin jar filled with 10mM 
sodium citrate buffer (pH 6) and then heated using microwave to 100°C for 10 
minutes. For proteinase K, sections were incubated at 37°C in 20 µg/mL 
proteinase K (Roche) in PBS for 10 minutes. Following either method, slides 
were then washed in PBS 3 times for 3 minutes each. 3% hydrogen peroxide in 
methanol was then added to each slide for 12 minutes to block endogenous 
peroxidase enzymes and then washed again in PBS 3 times, 3 minutes each. 
Sections were then protein blocked with Tris-NaCl blocking buffer (TNB, Perkin 
Elmer) for 30 minutes followed by incubation overnight at 4°C with desired 
primary antibody (see Table 1 for specific protocol for each antibody). 
 The next day, slides were then washed 3 times, 3 minutes each with 
either PBS or TNT buffer (1x TBS, 0.5% Tween-20) depending on the method of 
signal amplification. Sections were then incubated in corresponding secondary 
antibody diluted in TNB for one hour at room temperature. Signal was then 
amplified using a variety of methods depending on the primary antibody including 
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tyramide amplification (Perkin Elmer) and Avidin-HRP Amplification Kit (ABC; 
Vector). Antibody binding was detecting using DAB Chromagen Kit (Vector) and 
incubated in DAB solution for up to 20 minutes using light microscopy. Brown 
precipitates denoted positive signal. Slides were then rinsed in water, 
counterstained using hematoxylin (Sigma-Aldrich) and Tacha’s Bluing Solution 
(BioCare Medical) to stain all nuclei blue and then dried overnight. The following 
day, slides were mounted using xylene and permount (Fisher). 
 For fluorescence imaging, antigen was visualized using FITC (green 
color) or Texas Red and then counterstained using Hoescht solution (blue color, 
Invitrogen). Slides were mounted using Clear-Mount with Tris-Buffer (Electron 
Microscopy Sciences), sealed with clear nail polish and then stored in dark at 
4°C.  
Table 1 | IHC Specifics | Details on methods used for each particular IHC antibody.   
Primary 
Antibody 
Antigen 
Retrieval 
Secondary 
Antibody 
Amplification 
Method 
Wash Buffer 
Rabbit anti-
mouse Nrp2 
(Cell Signaling) 
– Dilute 1:100 
Sodium citrate 
pH 6 
Biotinylated 
anti-rabbit 
(Vector) – 
Dilute 1:300 
ABC 
amplification kit 
(Vector) or SA-
FITC (1:100) 
PBS 
Rat anti-mouse 
CD31 (BD 
Pharmigen) – 
Dilute 1:100 
Proteinase K Biotinylated 
mouse-
absorbed, anti-
rat (Vector) – 
Dilute 1:300 
Streptavidin 
(SA) HRP 
(Perkin Elmer; 
1:100); 
Biotinylated 
tyramide 
(Perkin Elmer; 
1:50); SA-HRP 
(1:100) 
TNT after 
primary 
antibody; PBS 
before 
Chicken anti-
mouse GFP 
(Abcam) – 
Dilute 1:500 
Sodium citrate 
pH 6 
Anti-chicken 
IgY HRP 
(Abcam) – 
Dilute 1:500 
None PBS 
 34 
Hamster anti-
mouse 
podoplanin 
(ReliaTech) – 
Dilute 1:100 
Proteinase K Anti-Syrian 
hamster HRP 
(Vector) – 
Dilute 1:300 
Biotinylated 
tyramide (1:50); 
SA-HRP or SA-
FITC (1:100) 
TNT after 
primary; PBS 
before 
 
Mice 
 Mice were maintained under pathogen-free conditions in a facility 
accredited by the Association for Assessment and Accreditation of Laboratory 
Animal Care (AAALAC). All procedures and care for the animals was in 
accordance with current regulations set by the US Department of Agriculture, 
Department of Health and Human Services, NIH, and approved by the 
Institutional Animal Care and Use Committee (IACUC) at Boston Children’s 
Hospital. 
 Nrp2+/gfp mice (Nrp2tm1.2Mom/MomJ, Stock #006700) were purchased 
from The Jackson Laboratory and maintained in C57BI6 (black coat) 
background. Nrp2+/gfp mice were bred with other heterozygotes to yield Nrp2gfp/gfp 
which were viable and fertile. They were used in this study to decipher the role of 
NRP2 in both pathological and physiological angiogenesis. Experiments were 
performed on wild-type (Nrp2+/+ or WT), heterozygote (Nrp2+/gfp or Hets), and 
knockout (Nrp2gfp/gfp or KOs) littermates obtained from breeding.  
Genotyping of Nrp2 Transgenic Mice 
 Bred mice were weaned at 3 weeks and genotyped. A different piece of 
ear was taken from each mouse in a cage to use for genotyping and 
distinguishing the mice in the future. Because these are GFP transgenic mice 
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and NRP2 is expressed by melanocytes in the hair follicles, the ears were 
observed under the fluorescent microscope for evidence of GFP. Mice were then 
placed in two groups based on the results of microscopy – WT group (no GFP 
positive hair follicles) and Het/KO group (GFP positive hair follicles). See Figure 
9 for an example of each result. The ears in the Het/KO group were then sent to 
Transnetyx where PCR was used to determine if they were NRP2+ 
(heterozygous) or Nrp2- (knockout). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 | Genotyping of NRP2 Transgenic Mice | A. Fluorescence microscopy of 
GFP-positive hair follicles from mouse indicating GFP is present (4X). B. Fluorescence 
microscopy of GFP negative hair follicles indicating that no GFP is present. Note: hairs 
are auto-fluorescent and appear green in all mice. C. Report from Transnetyx indicating 
a Het mouse (+) or a KO mouse (-).  
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Wound Healing Assay 
 One day prior to assay, fur from back of mice was shaved to reveal 
bare skin on the entire dorsal midline. Five mice from each group (WT, Het, and 
KO) were used in wound healing assay. On the day of the wounding, mice were 
anesthetized in a chamber containing 4% isoflurane and the back of mouse was 
sterilized with ethanol and iodine swabs. The mice were then laid on their sides, 
skin pinched back, and a 6 mm biopsy punch was used to make two 6 mm full-
thickness subcutaneous wounds on the back of each mouse. Mice were given 
analgesic (buprenorphine) once every twelve hours for the next 36 hours.  
 Immediately following wounding, transparency paper was used to 
outline the wound and measure its size. Wound size measurement was repeated 
every other day until all wounds were healed. IP Labs software was used to 
quantify the area of the wounds after they were traced onto transparency paper 
and digitally scanned. Percent of area healed was plotted versus the time after 
wounding for each group and compared using Excel. Unpaired t-test was used 
for statistical analysis. 
Delayed Type Hypersensitivity Reactions 
 DTH reactions were induced in the ear skin of Nrp2 transgenic mice 
(n=6 mice per WT, Het, & KO group). Skin was sensitized by topical application 
of 2% oxazolone (4-ethoxymethylene-2-phenyl-2-oxazoline-5-one; Sigma) in 
acetone/olive oil solution in 4:1 vol/vol solution. This solution was added to each 
paw (5 µL) and abdomen (50 µL). On the fifth day after sensitization (day 0), 20 
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µL (10 µL each side) of a 1% oxazolone solution was applied to one ear of each 
mouse. The thickness of the ears was measured using a sensitive caliper daily 
for 11 days. The increase in ear thickness from baseline (day 0) for each mouse 
was used to determine the amount of inflammation. The change in ear thickness 
was plotted versus time using Excel. Unpaired t-test was used for statistical 
analysis.  
Pancreatic Tumor Inoculation 
 Panc0H7 cells, a mouse C57BI6 pancreatic adenocarcinoma cell line 
(syngeneic to our Nrp2 transgenic mice), were provided by Dr. Keping Xie (MD 
Anderson Cancer Center, Houston, TX) and cultured in collaboration with Dr. 
Dipak Panigrahy (Boston Children’s Hospital). The cells were mixed in a 1:1 
volume ratio with matrigel (BD Biosciences), a material composed of extracellular 
matrix proteins that aids in tumor-take and hardens to keep tumor cells from 
leaking from the injection site. The cells were prepared so that 40 µL of solution 
would contain 106 total Panc0H7 cells and that volume was injected into the 
pancreas of each mouse. 
 The cells were aspirated into a 1 mL syringe and a precision push 
button dispensing device (Hamilton) was added to the syringe along with a 30 
gauge needle for injection. The syringe was kept on ice between each injection 
so that the matrigel would not harden prematurely. The Panc0H7/matrigel 
mixture was injected orthotopically into female WT, Het, and KO Nrp2 transgenic 
mice (n=5 from each group).  
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 Mice were anesthetized in a chamber containing 4% isoflurane and 
then transferred to the operating table where they were given isoflurane 
throughout the procedure via a nose cone. The skin around the incision site was 
sanitized with iodine and alcohol before a 1-1.5 cm incision was made on the left 
abdomen of the mouse. The mouse spleen was then externalized with a cotton 
swab in order to expose the attached pancreatic tissue. The tumor cell and 
matrigel mixture (40 µL) was then injected orthotopically into the mouse pancreas 
and held in place for ten seconds so that the matrigel would solidify. After 
solidification, the spleen and pancreas were returned to the abdomen and wound 
clips (Autoclip) were used to close the incision. Mice were allowed to recover in 
cages under a heating lamp and were given analgesic every 12 hours for 48 
hours after surgery. The staples were removed one week after injection when the 
incision was healed and tumor size was monitored every 2 days by palpation. 
 Seventeen days after injection, all mice were sacrificed and tumors 
were resected. The pancreas, spleen, and liver were weighed and then fixed in 
10% buffered formalin overnight, transferred to 70% ethanol and finally 
processed and embedded in paraffin. In addition, levels of ascites and other 
remarkable observations in the tumor bearing mice were noted. Tumor weights 
and organ weights were averaged among the groups and graphed. Unpaired t-
test was used for statistical analysis. 
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RESULTS 
 
Nrp2 is expressed in numerous different organs and cell types 
 To deduce Nrp2 expression in murine organs, WT mice were sacrificed 
and then protein was isolated from brain, heart, lung, skin, pancreas, liver, 
uterus, and intestine. These protein lysates were separated by 7.5% SDS-PAGE, 
transferred to nitrocellulose, then immunoblotted with anti-Nrp2 antibody to 
quantify relative Nrp2 protein expression amongst organs (see Figure 10). Of the 
organs studied, the intestine most strongly expressed Nrp2 which confirmed 
previously reported data (Bielenberg et al. 2012). The intestine also showed the 
highest levels of soluble Nrp2 (sNrp2). Previous studies in the lab have shown 
that the band observed at 80-85 kDa is likely sNrp2 but it is also possible that this 
band could be attributed to degraded protein. In addition, the brain, skin, lung, 
and uterus all showed relatively higher levels of Nrp2 than other organs. This is 
the first time uterus has ever been shown to express Nrp2. Because Nrp2 is 
expressed on a variety of different cell types, western blot analysis only 
describes the relative amount of protein in each organ, but tells us nothing about 
the nature of its expression.  
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Figure 10 | Nrp2 expression measured by western blot | Nrp2 protein levels were 
measured from WT organ lysates. The anti-NRP2 antibody also detects what is likely a 
soluble form of Nrp2 (sNrp2) which is around 80-85 kDa. The blot was stripped and 
reprobed for GAPDH, to evaluate loading. 
  
Nrp2 is differentially expressed on EC and LEC in organs  
 Based on our growing knowledge of NRP expression on various 
different cell types, organs were then explored for their differential expression of 
Nrp2. The lung and intestine were chosen for investigation based on their high 
expression of Nrp2 in the western blot analysis. 
 Serial sections of Nrp2+/gfp (Het) mouse colons were stained with 
podoplanin, a lymphatic EC marker, as well as Nrp2 (see Figure 11A&B). 
Previous studies have shown that smooth muscle in the bladder highly expresses 
Nrp2 and Figure 11A demonstrates it does in the colon as well. Figure 11C 
provides a schematic of the intestinal villus which features the lacteal, a 
lymphatic vessel the travels up each villus as well as blood vessel capillaries 
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wrapping around the lacteal. Podoplanin staining (Figure 11B) shows that each 
villus, cut longitudinal, has this podoplanin posititive lacteal. Interestingly, many 
of these lacteals are also positive for Nrp2 (Figure 11A) but the staining appears 
to show that not every lacteal is positive. This may be the result of tissue 
sectioning or there could be something regulating differential expression of Nrp2 
on the lacteal.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 | Nrp2 expression on colon lacteal | A) Section of mouse colon stained with 
Nrp2 antibody (brown). Arrows point to lacteals positive for Nrp2 and star signifies the 
Nrp2 positive smooth muscle (10X). B) Serial section of mouse colon stained with 
podoplanin (brown) which is expressed on lymphatic EC in the lacteal while SM layer is 
negative (10X). C) Diagram of intestinal villus adapted from Hole's Essentials of Human 
Anatomy & Physiology, 9/e, 2006, McGraw-Hill. 
 
 Based on the western blot (Figure 10), we then explored the expression 
of Nrp2 on lung ECs. Serial sections of mouse lung tissue were stained with 
CD31, an EC marker, and Nrp2 antibodies (Figure 12). As expected, CD31 is 
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strongly expressed on pulmonary veins and arteries in the lung (Figure 12A/C on 
“v” and “a”) but not bronchioles. Nrp2 was expressed on EC’s of those same 
veins but its expression was very heterogeneous and it was only expressed on a 
few ECs per vessel (Figure 12B). In addition, Nrp2 expression was confined to 
pulmonary veins and not present on pulmonary arteries (Figure 12D, arrows). 
This specific expression pattern has been previously reported in other tissues 
during development (Herzog, Kalcheim, Kahane, Neufield, 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 | Nrp2 expression on lung EC | Sections of lung tissue were stained with 
CD31 (A,C) and Nrp2 (B, D) antibodies (10X). CD31 is expressed on all endothelial cells 
in the lung while Nrp2 is present only on endothelial cells of the pulmonary veins (D). In 
D, arrows point to Nrp2 positive areas of the vessels. (a= artery/arteriole, v=vein/venule, 
br=bronchiole).  
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Nrp2 is more highly expressed on brown adipose tissue than white 
 Previously in the lab, Bernadette Zwaans stained Nrp2/LacZ E18 
embryos with X-gal, which produces a blue precipitate in locations where Nrp2 is 
endogenously expressed. Interestingly, the scapular area of the embryo was very 
positive (blue; Figure 13). The scapular region in young mammals is highly 
composed of brown adipose tissue (BAT). 
 
 
 
 
 
 
 
 
 
 
Figure 13 | Nrp2/LacZ E18 Embryo strongly positive in scapular region | E18 
Nrp2+/LacZ embryo was stained with X-gal and blue regions signify positive Nrp2 
expression. The circle surrounds the scapular region of the embryo which is largely 
composed of BAT. WT (Nrp2+/+) embryo shows no blue because it has no LacZ gene 
and does not form any blue precipitate when exposed to X-gal.  
 
  
 
 
 44 
 Nrp2 protein expression was then explored in white adipose tissue 
(WAT) and BAT from WT and Het mice via western blot. As shown in Figure 14, 
BAT much more strongly expresses Nrp2 than WAT in adult mice (compare 
lanes 1 and 3). This is a novel finding and we are the first group to explore 
expression of Nrp2 in WAT and BAT. P3 brown fat strongly expresses Nrp2 
(Figure 14, lane 5). As expected, heterozygous Nrp2 mice express approximately 
half as much Nrp2 protein in BAT as WT mice in both adult (compare lanes 3-4) 
and newborn mice (compare lanes 5-6). Nrp2+/- WAT (lane 2) was not equally 
loaded so it could not be compared to Nrp2+/- BAT. P3 WAT was not isolated. 
This finding was confirmed by the gene portal system, BioGPS, which shows 
higher levels of Nrp2 RNA in BAT than WAT (Lattin et al., 2008).  
 
 
 
 
 
 
 
 
 
 
 
Figure 14 | Nrp2 expression is higher in brown adipose than white adipose tissue | 
Protein isolated from WT and Het Nrp2 transgenic mice (both adult and 3-day old) was 
immunoprobed with anti-Nrp2 antibody. Brown fat lysates had higher levels of Nrp2.  
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Nrp2 expression in mouse skin 
 Previous studies by Bernadette Zwaans in the lab have shown that 
Nrp2 is expressed on a number of different cell types in the skin (see Figure 15). 
Based on the X-gal staining, Nrp2 appears to be very highly expressed on vessel 
ECs during development but there are less Nrp2 positive vessels in adulthood 
(Figure 15B). It is, however, expressed on melanocytes and SM pili that are 
found in the skin of adult mice. Our western blot analysis (Figure 10) showed the 
skin to be a high expresser of Nrp2, even in the adult. The expression of Nrp2 in 
the skin leads us to hypothesize that both cutaneous wound healing and delayed 
type hypersensitivity reactions may both be affected by loss of Nrp2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 | Nrp2 expression in E18 and adult mouse skin | A) Section of dorsal skin 
taken from Nrp2+/LacZ E18 embryo showing Nrp2 expression (blue) on many vessels 
(20X). B) Section of dorsal skin taken from Nrp2+/LacZ adult mouse showing reduced Nrp2 
expression on vessels but strong expression in melanocytes (red arrow) and arector pili 
SMC (yellow arrow) (20X). 
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Wound healing not affected by loss of Nrp2 
 Based on Nrp2 expression in the skin, we anticipated that cutaneous 
wound healing would be slowed in Nrp2 knockout mice compared to their Het 
and WT littermates. Wound healing assays were performed on Nrp2 transgenic 
mice with differing results between two trials. Figure 16A illustrates the first 
wound healing assay where 6 mm sub-cutaneous wounds were made on the 
back of five WT, Het, and KO mice. In this trial, the WT mice healed at a slower, 
yet not statistically significant, rate than the Het and KO groups. Due to the fact 
that the KO mice are deficient for a key angiogenic regulator, these results were 
puzzling. In the wound healing process, angiogenesis does not begin until the 
proliferative phase, which begins about 72 hours after wound infliction (Falanga, 
2005). The KO mice have the shallowest rate of healing from day 3 onward, 
however this finding was also not statistically significant. 
 Because the WT wound healing data was puzzling in the first trial, the 
assay was repeated with only WT and Het mice (Figure 16B). In this trial, there 
was virtually no difference between the two groups indicating that the first WT 
trial may have been due to trial error. The assay was not repeated with KO mice 
but if the KO data from the first trial were superimposed into the second trial, 
there would be very little difference between the three groups. The only slight 
difference would be a sharp decrease on day 1 whereas the WT/Het groups both 
showed very little contraction over the first 24 hours.  
  
 47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 48 
 
 Figure 16C/D shows histological data at various time points after dorsal 
incisional wounds (not punch biopsy) were performed in Nrp2/LacZ transgenic 
mice. Bernandette Zwaans provided this data. During both time points after the 
wound was made, there are very few Nrp2 positive (blue) vessels. There are, 
however, a great number of new blood vessels infiltrating the wound as indicated 
by the corresponding CD31 (brown) staining. These results may indicate that 
wound healing is not significantly dependent upon Nrp2 positive vessels. 
Nrp2 deficient mice show stronger, delayed ear swelling 
 Because Nrp2 has been shown to be important in proper lymphatic 
vessel formation, we hypothesized that Nrp2 KO mice may respond differently to 
inflammation than their littermates. An oxazalone induced delayed-type 
hypersensitivity assay using the Nrp2 transgenic mice was performed (Figure 
17). All mice in the three groups swelled to about the same size one day after 
being challenged with oxazalone (350-400 µm). After day one, Nrp2 deficient KO 
mice displayed persistent swelling of at least 300 µm until day five that was of 
statistical significance. In fact, as WT and Het mice began to recover on day two, 
the KO mice actually showed increased swelling on the second day. Nearly all 
WT and Het mice recovered to normal ear size by the end of the 11 day trial. KO 
mice, however, took considerably longer to fully recover to normal ear size with 
some showing persistent swelling at 21 days.  
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 Interestingly, the Het group behaved very similarly to the WTs, reaching 
the same level of swelling and then recovering at nearly an identical pace. The 
Het mice produce half as much Nrp2 as their WT littermates but that appears to 
be enough for physiological recovery from swelling. The KO’s significant inability 
to recover at the same rate as their littermates indicates that Nrp2 may play a key 
role in draining lymph after swelling.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 | DTH Assay | NRP2 KO mice show prolonged ear swelling in comparison to 
WT and Het groups. DTH reactions were induced by oxazolone application to the ear 
and then monitored over the next 11 days. Ear swelling is expressed by the increase in 
micrometers of the ear. The ear swelling of the KO group (solid triangle, solid line) was 
prolonged in comparison to the Het (solid square, dashed line) and WT (solid circle, 
dashed line) groups. * indicates P<0.01 
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 The DTH was performed a second time and mice were sacrificed at day 
4 and ears were taken for histology. Figure 18 shows both H&E (A-C) and CD31 
(D-F) fluorescent staining of ears from all three groups (WT, Het, and KO). KO 
mice showed dramatically higher swelling, as expected, on day 4 than both Hets 
and WTs. Interestingly, the outer region of the ear displayed the most dramatic 
swelling in all mice. CD31 staining showed a greater number of large vessels in 
the Het and WT ears in comparison to knockout ears. This is only a preliminary 
observation and vessel density should be analyzed more thoroughly in these 
mice.  
 
 
 
 
 
 
 
 
Figure 18 | Histology of DTH ear swelling in Nrp2 transgenic mice | Panels A-C 
illustrate H&E staining of WT, Het, and KO ears displaying largest swelling in the KO and 
larger swelling in the outer ear in all three groups (10X). Panels D-F show fluorescent 
CD31 staining of just one field of each ear displaying smaller vessels in the KO ear 
(20X).  
 
 
 
 51 
Nrp2 deficient mice have smaller tumors and less metastasis 
 Because Nrp2 has been demonstrated to play a key role in 
angiogenesis and lymphangiogenesis, we anticipated that Nrp2 KO mice would 
have fewer metastases than their WT and Het littermates. A fast growing 
syngeneic murine pancreatic adenocarcinoma cell line, Panc0H7, was injected 
orthotopically into the pancreas of WT, Het, and KO Nrp2 transgenic mice. This 
is an extremely fast growing cell line and the mice were sacrificed after just 17 
days of growth. Despite the short time of growth, mice displayed significant tumor 
growth, metastasis, and development of ascites. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 | Panc0H7 tumors grown in Nrp2 transgenic mice | A) Mass comparison of 
the pancreas, liver, and spleen between the WT, Het, and KO groups. KO pancreas 
mass was significantly lower than WT pancreas mass and KO liver mass was 
significantly lower than both Het and WT liver masses. B) Gross depiction of WT, Het, 
and KO pancreatic tumors depicting a stepwise decrease in size from WT to Het to KO 
groups. * indicates P<0.01.  
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 Figure 19A displays the average mass of the pancreas and two of the 
most common metastatic sites, liver and spleen. Average pancreatic mass 
decreased in a stepwise fashion from WT (1.11 g) to Het (0.91 g) to KO (0.69 g), 
but only the difference between KO and WT was of statistical significance. 
Similarly, there was a stepwise decrease in mass seen in both the liver and 
spleen. There was no statistical significance between the spleen masses but the 
lower liver mass of the knockout was significant. The average liver weight in the 
KO group was 0.70 g whereas the Het and WT groups had average liver weights 
of 0.98 and 0.99 g, respectively. Figure 19B shows a gross depiction of all the 
resected pancreatic tumors. There was considerably more healthy pancreatic 
tissue in the KO group than both the Het and WT groups. 
 In humans, PDAC mortality is most often caused by liver failure due to 
metastasis to the liver. In this model, gross liver metastases were not observed in 
any group. This is likely due to the short overall time of growth. However, WT and 
Het livers were larger than KO livers suggesting that histology may show 
microscopic liver metastases in the WT/Het groups. In addition, there was a 
reduction in overall metastases in the KO group (Table 2). All of the WT (n=4) 
and Het (n=4) showed many intestinal, diaphragm, and spleen metastases 
whereas the KO group showed either an absence of metastases or only a few 
per site. In addition, the KO mice displayed considerably less ascites and 
appeared to have more healthy liver tissue.   
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Table 2 | PancOH7 metastasis and ascites in Nrp2 transgenic mice| Qualitative 
analysis of intestinal, diaphragm, and spleen metastases in WT, Het, and KO mice 
showing reduced metastases in KO group. In addition, KO mice had reduced amounts of 
ascites. *Each of the 5 KO mice showed just one small metastasis to the diaphragm 
while each in WT and Het groups displayed many metastases **The one KO mouse with 
spleen metastasis had one small metastasis while the Het and WT groups showed many 
metastases.  
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DISCUSSION 
 
 As our understanding of NRP2 increases so does the complexity of its 
function and expression. Because its expression is becoming more and more 
widespread, an immunoblot for NRP2 protein expression in various organs paints 
a rather limited picture of its involvement in angiogenesis and other physiological 
phenomena. For example, the intestine displayed the highest level of protein in 
Figure 10, but a large amount of that expression is limited to the visceral smooth 
muscle. To the same token, the majority of the protein expression seen in the 
brain in Figure 1 is due to NRP2’s role on neurons. Our novel finding that NRP2 
is more highly expressed in brown adipose tissue than white is the most recent 
discovery involving NRP2’s interestingly complicated expression pattern. 
 Adipose tissue in mammals can be divided into two distinct types, white 
and brown, which have almost entirely opposite functions. The main function of 
WAT is that of a storage depot; it stores excess calories as triacylglycerides 
which can be later metabolized in the starved state. BAT, on the other hand, is 
filled with mitochondria which burn calories at a high rate in order to produce heat 
when the organism is in cold conditions (Saely, Geiger, Drexel, 2012). For many 
years, BAT was thought to be solely found in newborn mammals, but recent 
studies have shown that adults too have BAT in multiple locations throughout the 
body (Wehrli et al., 2007). BAT has also been identified as a more vascularized 
tissue than WAT (Cinti, 2009). This finding gives some precedence to our 
discovery, but it is unknown whether the large difference in NRP2 expression is 
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solely due to a higher vessel density. It is possible that NRP2 could also be 
expressed on the adipocytes, with a function that is currently unknown. Double 
staining of BAT sections using CD31 and NRP2 or NRP2 and perilipin (an 
adipocyte marker) could elicit which cell types express NRP2 in BAT. Because 
the amount of WAT is directly correlated with incidence of type II diabetes 
mellitus, the calorie-burning BAT has been identified as a potential therapeutic 
tool (Bartelt and Heeren, 2012). NRP2 could potentially play a key role in this 
process.  
Because we are still learning which cell types express NRP2, a western 
blot cannot shed much light onto which organs would be most sensitive to anti-
angiogenic therapies targeting NRP2. In order to help understand this, IHC is 
essential. However, IHC is further complicated by the fact that all of our Nrp2 
antibodies detect both the soluble and receptor version of Nrp2. Positive 
indication of Nrp2 could be either full length or sNrp2 and developing methods to 
distinguish between the expression of the two is needed. Based on IHC, it does 
not appear as if there is a set of rules for where and how NRP2 is expressed on 
ECs. From the IHC data, it is clear that NRP2 is most frequently found on LECs 
in adult mice, but is not expressed on every LEC. This is particularly true on the 
intestinal lacteal; many do express NRP2 but it does not appear that they all do. 
Further, NRP2 expression is also seen on some vascular ECs but its expression 
again shows very little consistency. This is particularly true in lung EC. Figure 12 
shows that many pulmonary vein EC express NRP2 but certainly not every EC in 
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the vessel. For the most part, there was no NRP2 expressed on LEC in the lung 
which was also surprising. This complicated expression pattern begs the 
question: what is regulating NRP2 expression?  
Different physiological angiogenic assays could elicit information into how 
NRP2 is regulated in adult physiology. It did not appear as if cutaneous wound 
healing was dependent upon NRP2 as the Nrp2 KO mice healed at 
approximately the same rate as their Het and WT littermates. Angiogenesis is 
involved in wound healing, but it appears as if this method is largely NRP2 
independent. It is potentially possible, however, that the Nrp2 KO mice over 
express other angiogenic factors in order to compensate for the loss of NRP2. 
The shallower slope of healing in KOs after angiogenesis traditionally begins 
indicates that perhaps the loss of NRP2 has some role, albeit very minimal. 
Because the histology of the wound healing site showed very few positive 
vessels (Figure 16C/D), however, the data suggests that it is more likely that 
adequate wound healing is not heavily dependent upon NRP2. For potential anti-
NRP2 cancer therapy, this is ultimately a positive finding. It is unlikely that 
patients being treated with SEMA3F or another molecule that targets NRP2 
would have any problems healing from wounds that they may encounter during 
treatment.  
Interestingly, the site of wound healing may also be crucial in determining 
whether NRP2 plays a role. In a previous study performed in our lab by 
Bernadette Zwaans and Dr. Diane Bielenberg that has not yet been published, a 
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corneal suture assay in the eye of the mouse shows drastic NRP2 positive vessel 
growth in response to the suture assay (Figure 20). The shape of these vessels 
appear thick and more lymphatic looking while the CD31 vessels are thin and 
wispy. This may indicate that the corneal suture assay induces NRP2 dependent 
lymphangiogenesis while cutaneous wound healing may not require a large 
amount of lymphangiogenesis causing it to be NRP2 independent.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 | Corneal Suture Assay | Corneal suture assay induces large increase in 
NRP2 positive lymphatic vessels. A) X-gal staining of cornea after suture assays shows 
many newly sprouted vessels (blue) that are positive for NRP2. B) The same eye 
stained with anti-CD31 antibody shows many blood vessels growing in the cornea after 
the assay which do not overlap with the x-gal staining suggesting that blood capillaries 
do not express Nrp2 in the suture model.  
 
Our data indicates that NRP2 does play a role in recovery from swelling as 
indicated by the persistent swelling seen in KO mice ears after being challenged 
with allergen. It has been shown previously that a VEGF-C adenovirus in the ear 
can drastically increase lymphatic vessel sprouting in mice. These new lymphatic 
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vessels also persisted after the stimulation was removed (Dvorak & Mihm, 1972; 
Wirzenius et al., 2007). It is likely that the swelling due to DTH also induces 
lymphangiogenesis and lymphatic vessel sprouting in order to help drain the 
accumulated lymph. The persistent swelling seen in KO mice likely indicates that 
their lymphatic vessels are not capable of draining lymph at the same rate as 
their WT and Het littermates. Perhaps the mice have reduced numbers of 
lymphatic vessels or flawed lymphatic vessels that impede the draining of lymph. 
Preliminary CD31 staining does show a reduced number of large vessels in the 
DTH ears of KO mice. Previous DTH studies on other transgenic mice also 
compliment these findings. Mice over expressing VEGF164 show even more 
prolonged and drastic swelling than what is seen in our NRP2 KO mice (Detmar 
et al.,1998). When this mouse line is crossed with mice over expressing sNRP1 
in the skin, that swelling is almost entirely reduced as sNRP1 acts as an inhibitor 
of VEGF164 induced vascular permeability (Mamluk et al., 2005). Our data 
suggests that NRP2 plays a pivotal role in lymphatic vessel formation and 
lymphangiogenesis and would be an excellent target for anti-lymphangiogenic 
therapies. Previous studies have shown that targeting NRP2 with an antibody 
does inhibit tumor lymphangeogenesis and our results here correlate with those 
findings (Caunt et al., 2008). 
A stark difference between wound healing and DTH is in how 
angiogenesis (or lymphangiogenesis) is induced. In wound healing, blood 
vessels are physically removed in the formation of the wound and, therefore, the 
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ensuing angiogenesis is induced by hypoxia and the necessity for new blood 
vessels to supply the wounded area. DTH, however, does not involve hypoxia 
and is largely driven by growth factor and cytokine release. Growth factors also 
mediate angiogenesis and lymphangiogenesis in the corneal suture assay shown 
in Figure 20. It is possible that NRP2 does not respond to hypoxia induced 
angiogenesis but is instead more sensitive to certain growth factors released 
during DTH and corneal suture assays. It has been shown previously that NRP2 
in SMC is upregulated by TGF-β and IGF while it is downregulated by PDGF and 
HBEGF (Bielenberg et al., 2012). It is unknown whether NRP2 in EC behaves 
similarly but it is possible that platelets in wound healing release PDGF that 
actually decreases NRP2 expression while other growth factors released during 
DTH induce NRP2 expression. We know that DTH involves the T-cell mediated 
release of many different growth factors at very high levels. It is possible that one 
or many of these growth factors somehow induce NRP2 expression.  
Further NRP2 studies should be aimed towards understanding NRP2’s 
intricate regulation. Our data shows that many factors could impact NRP2 
regulation and another possible factor could be ischemia. A hind limb ischemia 
assay performed in Michael Klagsbrun’s laboratory caused a great induction of 
NRP2, even in the femoral artery, which does not express NRP2 when 
unchallenged (Figure 21; Klagsbrun, Takashima, Mamluk, 2002). It would be 
interesting if NRP2 were induced by ischemia but not hypoxia. At first thought, 
this seems perplexing, but it could be possible that NRP2 induction is a stop gap 
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mechanism only utilized in severe ischemic events. Perhaps less severe hypoxic 
events do not necessitate induction of NRP2 expression.  
 
 
 
 
 
 
 
 
Figure 21 | Hind limb ischemia in NRP2 mice | Hind limb ischemia assay showing an 
increase in NRP2 expression after ischemia. Arrow points to femoral artery. From 
Klagsbrun, Takashima and Mamluk, 2002.  
 
The significant decrease in tumor size and metastasis seen in our PDAC 
model demonstrates the potential efficacy of anti-NRP2 therapy. It is likely that 
using SEMA3F or another inhibitor of NRP2 would have an even more drastic 
effect on tumor growth and metastasis. In the KO model, the mouse does not 
make NRP2 but the tumor cells themselves still have it. In a therapeutic setting 
using SEMA3F, the NRP2 made by the tumor cells would also be inhibited. Our 
model here gives precedence to using SEMA3F as a potential antitumor agent. It 
is important to note that SEMA3F is not only an inhibitor of VEGF, but uses 
Plexin A1 to relay its own anti-angiogenic signal thereby tackling angiogenesis in 
two different ways. Further studies utilizing these mice in combination with a 
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classical VEGF inhibitor such as anti-VEGF antibodies or VEGFR2 kinase 
inhibitors would likely show even more inhibition of tumor growth and 
angiogenesis.  
Despite not having any grossly visible liver metastasis in this model, it is 
still possible that some micrometastases are present and sections should be 
stained with cytokeratin to investigate their presence. In addition, tumors should 
be stained for EC and LEC markers in order to see if the KO mice have lower 
vessel density. A decrease in vessel density in the KO mice would be expected 
given the phenotype of the mouse and would be a large contributing factor in 
their reduced tumor size and metastases.  
 
 
 
 
 
 
 
More extensive NRP2 research has led to exciting discoveries indicating 
its presence and function in cell types beyond just neurons and ECs. In addition, 
many groups have attempted to use NRP2 as a target for cancer therapy utilizing 
a variety of different methods (see Table 3). Most all of the attempted methods 
have been successful to a certain degree and that list could be expanded to 
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include the Nrp2 knockout model included in this study. Targeting NRP2 can be 
approached from a wide range of perspectives and its success warrants a 
greater look into the mechanisms that underlie its expression in the adult 
vasculature. The data presented in this report indicate that NRP2’s physiological 
role is widespread and complexly regulated. Anti-NRP2 therapies do 
demonstrate potentially significant efficacy, but more research into NRP2 is 
necessary in order to more fully understand exactly where and how that target is 
expressed.  
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